Back to News
Market Impact: 0.2
Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
Santa Ana Bio dosed the first subjects in its Phase 1 trial of SAB01, a first-in-class bispecific antibody targeting KIT and Siglec-6 to deplete mast cells. The milestone advances the company’s clinical development program, but efficacy and safety data have not yet been reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Fed chairman talks tough on inflation — plus, what's behind Micron's big rally
- Investors Eye AI Payoff in Microsoft, Alphabet Earnings
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- Apple brings touch to the Mac, reversing years-old stance on touchscreen laptop
- The 2,000-Nit OLED in Apple’s New MacBook Is a Big Deal